Breast Biopsy Market: By Product (Biopsy Needles, Biopsy Tables), Technique Type (Fine Needle Aspiration Biopsy, Core Needle Biopsy), Guidance Technology (Ultrasound-Guided, CT-Guided Biopsy), End-Users (Hospitals, Labs)- Forecast Till 2027

Breast Biopsy Market Overview:

The breast biopsy market is projected to reach USD 1104 million by 2027 at CAGR of 10.10%. A breast biopsy is a procedure usually done after mammography or ultrasound, only when a suspicious lesion or hard palpable lump is discovered in any of those test processes. The breast biopsy removes a sample of that suspicious tissue and is then sent to the pathologists to analyze the tissue. Palpable lumps and abnormalities can be discovered by physical, self-examination, or mammography; however such procedures can’t determine the abnormal growth is benign or cancerous. A breast biopsy is usually suggested when the doctor identifies a lump or thickening of the patient’s breast, or if the mammogram identifies a suspicious tissue in the patient’s breast. Therefore Breast Biopsy is not the initial procedure.

During the Biopsy, the loud clicking sound will be heard while the sample is collected from the patient’s body. The physician might move the needle around the suspicious area to collect the sample from different parts and collect about 8 samples for various test procedures. There are varied types in the biopsy procedures, most of which are minimally invasive procedures. The increasing prevalence of breast cancer cases across the globe and the minimally invasive procedure are driving the Breast Biopsy market growth in recent times.

COVID 19 Analysis:

Several surgical plans have been postponed due to the widespread of COVID. Since surgical procedures tend to increase the chances of getting an infection, surgeons have had to make difficult decisions to postpone elective surgeries. Additionally, the health care centers had to find alternative pathways to treat patients who are diagnosed with cancer or cancer suspects, since the cancer patients are more vulnerable to get affected by COVID.

Limited access to clinical centers, social distancing, and strict guidelines throughout the globe has significantly affected the growth of the Breast biopsy market. Potential delays in the cancer diagnosis or treatment could lead to life-threatening conditions and had to be balanced during the pandemic due to the risk of exposure to COVID infection. This factor was the major challenge during the early stages of the pandemic.

Market Dynamics:

Drivers:

Novel biopsy technique and the advent of new product approvals provides minimally invasive procedures. A 6mm Bergstrom side-cutting biopsy needle was considered as a successful instrument to obtain large pieces of tissue, under the guidance of ultrasound. Such new instruments and techniques have significantly impacted the overall growth of the Breast biopsy market.

Increasing incidences of breast cancer in recent years is the primary growth attributing factor for the Breast biopsy market. Over 265,000 cancer susceptive cases were diagnosed in the year 2018 and over 63,960 non-invasive procedures were carried out during the year. Such reports are stimulating the overall growth of the market.

Market opportunities:

Identifying cancer cells and DNA fragments have been a challenge in the medical industry, the advent of liquid biopsy has helped medical practitioners in identifying the circulating tumor cells precisely. Moreover, the necessity of surgeries and adverse effects of the surgeries such as scars could be eliminated with the process. The liquid biopsy can identify all of the genetic complexity of the tumors present in human breasts and is also capable of stopping them from spreading to other parts of the body. Such attractive features of the liquid biopsy have presented a lucrative opportunity for the overall Breast Biopsy Market growth.

The invasive procedures have brought in several adverse effects such as huge blood loss, surgical infection, and longer recovery time. However, the advent of minimally invasive alternatives such as image-guided biopsy has given accurate results. The increase in acceptance of image-guided needle biopsy is expected to drive the Breast Biopsy market growth in the forecast period.

Market restraints:

The surgical procedure in the biopsy tests carries adverse effects such as bruising the breasts, swelling, soreness, and post-surgery infection in the operated site. Some of the signs of infections such as warmth in breasts discharge from the site, redness in the site, or fever of over 100’f might be ignored by the patient which might take the situation to serious condition. Such factors are hindering the Breast biopsy market growth.

Some over-the-counter drugs have to be avoided post-surgery, herbs, drugs, vitamin or mineral drugs might contradict the medication administered during the biopsy. If the patient has not followed the advice of the medical practitioner, the condition gets worse. Such factors are considered as major restraining factors for the overall growth of the Breast biopsy market.

Market challenges:

Some developing countries possess poor treatment facilities, especially concerning cancer-related treatments. Poor health infrastructure in some countries, lack of skilled surgeons, and lack of essential resources are projected as major challenges for the Breast Biopsy market growth. A recent study shows that there would be a shortage of over 2300 medical oncologists in the US by the year 2025 while comparing with the rising cancer incidences.

Inadequate obtaining of tissue could make the entire process worthless, and possible false negative indications are some of the major restraining factors for the growth of the Breast biopsy market.

Cumulative growth analysis:

The advent of liquid biopsy has created a new dimension in the field of oncology. The liquid biopsy comes with several advantages over the tissue biopsy procedure. They are minimally invasive, therefore comes with minimal complications or adverse effects. Since the medical instrument utilized in the liquid biopsy is easier to handle, the process requires minimal medical skill and can be repeated when necessary. Moreover, the combination of droplet digital PCR technology and NGS-based assays has augmented the Breast Biopsy market growth in several countries.

The Breast Biopsy market value was at USD 1123 million in the year 2019, owing to the increasing prevalence of cancer patients and increased mortality rate due to breast cancer, the market value is expected to surpass over USD 1890 million by the year 2026 while registering a CAGR of 6%. Despite the challenges imposed due to the COVID infection spread, the alternative medical facilities have managed to favor the growth of the Breast biopsy market in recent times.

Value chain analysis:

There are a few options in the Biopsy procedures; the physician might choose the appropriate procedure according to the patient’s condition. If the patient is diagnosed with fluid-filled cysts in the breasts or nodules, or enlarged lymph nodes, the doctor might suggest a fine needle biopsy that is capable of reaching deeper and draws the fluid from the cyst or tissue sample. As the needles are very thin, even thinner than the ones used for blood tests, they are extremely painless.

On the other hand, if the physician decides to obtain the core tissue of the tumor. The Core needle biopsy is carried out. After administrating local anesthesia, the process is carried out. The needle has to be pierced few times to obtain several parts of the tumor. Although the procedure might take time more than the fine needle biopsy, accurate results are obtained through the procedure. Such diverse availability of options in the field has presented a lucrative opportunity for the Breast Biopsy market growth in the forecast period. The advent of the Tri-axial needle and increased utilization of this type of needle has enabled the physicians to obtain a clearer image in the Ultrasound or CT scans. Moreover, the needles help the health care professionals to obtain the tissue without compressing it. Under the guidance of CT or Ultrasound, the processes have attained higher success rates.

Segment overview:

Based on Product:

• Biopsy Needles


• Guidance Systems


• Biopsy Tables


• Localization Wires


• Assay Kits


• Liquid Biopsy Instruments


• Others

Based on Type:

• Needle Breast Biopsy


• Core Needle Biopsy (CNB)


• Fine Needle Aspiration Biopsy (FNAB)


• Vacuum-assisted Biopsy (VAB)


• Open Surgical Breast Biopsy


• Excisional


• Incisional


• Liquid Breast Biopsy


• Circulating Tumor Cells


• Circulating Tumor DNA 


• Other Biomarkers

Based on Guidance:

• Image-Guided Biopsy


• Mammography-guided Stereotactic Biopsy


• Ultrasound-guided Biopsy


• MRI-guided Biopsy


• Other Guidance Techniques


• Liquid Biopsy


• NGS-based Biopsy


• PCR-based Biopsy


• Microarray-based Biopsy

Based on Application:

• Early Cancer Screening


• Therapy Selection


• Treatment Monitoring


• Recurrence Monitoring

Based on End-user:

• Diagnostic Clinic


• Hospitals


• Others

Regional analysis:

Over other countries, North America is currently dominating the market share, accounting for over 42% in the year 2020. The region was diagnosed with over 62% of breast cancer cases in recent times. The advancing medical infrastructure and technology have augmented the overall growth of the market in the region. Moreover, the increasing awareness of identifying the palpable lumps in breasts, early identification, and self-examination have also impacted the Breast Biopsy market growth. 

The minimal invasive diagnosis and straightforward procedures have aided the growth of Breast Biopsy procedures. Several developed healthcare systems have obtained alternative treatment pathways owing to the restrictions imposed due to pandemics. 68% of the health care institutions in over 41 countries across the globe have recommended endocrine therapy in luminal A tumors. 

Competitive landscape:

• Medical Technologies LLC


• STERYLAB S.r.l.


• ARGON MEDICAL


• Danaher, Cianna Medical


• United Medical Systems Inc.


• Stryker


• Hologic Inc.


• Devicor Medical Products Inc.


• F. Hoffmann-La Roche Ltd


• OncoCyte Corporation


• Siemens, Medtronic


• Trivitron Healthcare


• Johnson & Johnson Services Inc.

Recent developments:

Recently, a leading biopsy center has announced a novel blood-based testing method; the supreme accuracy of the method has enabled physicians to perform complex biopsies with few procedures. The procedure has been extremely helpful owing to its accuracy in monitoring HER2 alterations in patients who were diagnosed with metastatic breast cancer.

In the year 2019, a European medical center has received approval for the Brevera Biopsy system which comes with Corlumina imaging technology. The technology enhances the procedure and increases the accuracy with a real-time imaging technique. The patients have felt reduced anxiety during the procedure and feel extremely comfortable throughout the procedure.

Report overview:

This report has covered:

• Market overview


• COVID 19 Analysis


• Market dynamics


• Cumulative growth analysis


• Value chain analysis


• Segment overview


• Regional analysis


• Competitive landscape


• Recent developments